MXPA05007846A - Derivados de diazepanes utiles como inhibidores de lfa. - Google Patents

Derivados de diazepanes utiles como inhibidores de lfa.

Info

Publication number
MXPA05007846A
MXPA05007846A MXPA05007846A MXPA05007846A MXPA05007846A MX PA05007846 A MXPA05007846 A MX PA05007846A MX PA05007846 A MXPA05007846 A MX PA05007846A MX PA05007846 A MXPA05007846 A MX PA05007846A MX PA05007846 A MXPA05007846 A MX PA05007846A
Authority
MX
Mexico
Prior art keywords
lfa
diazepanes
inhibitors
derivatives useful
icam
Prior art date
Application number
MXPA05007846A
Other languages
English (en)
Inventor
Gottfried Meingassner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0301561A external-priority patent/GB0301561D0/en
Priority claimed from GB0323976A external-priority patent/GB0323976D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05007846A publication Critical patent/MXPA05007846A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen diazepanes farmaceuticamente activos, por ejemplo, utiles para el tratamiento de trastornos o enfermedades mediadas por interacciones de LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/CAM-3 o LFA-1/JAM-1.
MXPA05007846A 2003-01-23 2004-01-22 Derivados de diazepanes utiles como inhibidores de lfa. MXPA05007846A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0301561A GB0301561D0 (en) 2003-01-23 2003-01-23 Organic compounds
GB0323976A GB0323976D0 (en) 2003-10-13 2003-10-13 Organic compounds
PCT/EP2004/000514 WO2004065382A1 (en) 2003-01-23 2004-01-22 Diazepanes derivatives useful as lfa inhibitors

Publications (1)

Publication Number Publication Date
MXPA05007846A true MXPA05007846A (es) 2006-02-10

Family

ID=32773971

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007846A MXPA05007846A (es) 2003-01-23 2004-01-22 Derivados de diazepanes utiles como inhibidores de lfa.

Country Status (19)

Country Link
US (1) US7419976B2 (es)
EP (1) EP1590342A1 (es)
JP (1) JP4644655B2 (es)
KR (1) KR20050095618A (es)
AR (1) AR042740A1 (es)
AU (1) AU2004205504B2 (es)
BR (1) BRPI0406884A (es)
CA (1) CA2509764A1 (es)
CO (1) CO5580804A2 (es)
EC (1) ECSP055917A (es)
MX (1) MXPA05007846A (es)
MY (1) MY141850A (es)
NO (1) NO20053911L (es)
NZ (1) NZ540867A (es)
PE (1) PE20040941A1 (es)
PL (1) PL376540A1 (es)
RU (1) RU2347783C2 (es)
TW (1) TWI311557B (es)
WO (1) WO2004065382A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2463268B1 (en) * 2004-12-02 2013-08-28 Daiichi Sankyo Company, Limited 4-(Aminomethyl)benzoic acids as intermediates for the preparation of chymase inhibiting 1,4-diazepan-2,5-dione compounds
GB0507918D0 (en) * 2005-04-19 2005-05-25 Novartis Ag Organic compounds
WO2010126968A1 (en) * 2009-04-28 2010-11-04 Optmed, Inc. Compositions and methods for treating or preventing urolithiasis and conditions associated therewith

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ECSP003707A (es) * 1999-10-13 2002-05-23 Novartis Ag Diazepanes
US6399599B1 (en) * 1999-10-13 2002-06-04 Novartis Ag Substituted 2-oxo-1,4-diazacycloalkanes
AR030817A1 (es) * 2000-10-02 2003-09-03 Novartis Ag Derivados de diazacicloalcanodiona
EP1347968A1 (en) 2000-11-28 2003-10-01 Genentech, Inc. Lfa-1 antagonist compounds

Also Published As

Publication number Publication date
WO2004065382A1 (en) 2004-08-05
CA2509764A1 (en) 2004-08-05
CO5580804A2 (es) 2005-11-30
NO20053911L (no) 2005-10-24
NZ540867A (en) 2007-09-28
US20060148780A1 (en) 2006-07-06
TWI311557B (en) 2009-07-01
AU2004205504B2 (en) 2007-09-20
RU2347783C2 (ru) 2009-02-27
KR20050095618A (ko) 2005-09-29
EP1590342A1 (en) 2005-11-02
JP2006515335A (ja) 2006-05-25
BRPI0406884A (pt) 2006-01-03
PL376540A1 (pl) 2006-01-09
TW200418817A (en) 2004-10-01
US7419976B2 (en) 2008-09-02
AR042740A1 (es) 2005-06-29
PE20040941A1 (es) 2005-01-24
JP4644655B2 (ja) 2011-03-02
RU2005126459A (ru) 2007-02-27
NO20053911D0 (no) 2005-08-22
MY141850A (en) 2010-07-16
AU2004205504A1 (en) 2004-08-05
ECSP055917A (es) 2005-11-22

Similar Documents

Publication Publication Date Title
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MY140767A (en) Compounds, methods and compositions
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
ATE451376T1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
TW200720268A (en) 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
WO2001087328A3 (en) Interleukin-1 inhibitors in the treatment of diseases
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MY145074A (en) Thiazolidin-4-one derivatives
EA200701164A1 (ru) Способ получения аннелированных производных пиперазин-2-она и соответствующие промежуточные продукты
TW200509910A (en) Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
MX2010007391A (es) Antagonistas de trpa1.
WO2006047032A3 (en) Indole compounds useful as serotonin selective agents
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
WO2005016883A3 (en) Acrylamide derivatives as vla-1 integrin antagonists and uses thereof
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
NO20051663L (no) Fremgangsmater for behandling av neurodegenerasjon
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
WO2005019200A3 (en) Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration